Clinical Trial Update: A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia [Phase 2]

View source ↗

Summary

This is a completed Phase 2 trial assessing the safety of E2020 (donepezil) 10 mg, followed by an open-label extension with E2020 SR 23 mg, in Japanese subjects…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• E2020 10 mg (donepezil)
• E2020 SR 23 mg (donepezil)

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Type Dementia | Phase 2 | Status: COMPLETED | Results posted: 2014-08-01